Godavari Biorefineries raises Rs 90 crore in equity

The money raised is expected to fund an expanded facility for its R&D

vice-pres

Mr Samir Somaiya, chairman, Godavari Biorefineries

Godavari Biorefineries, one of India's sustainable manufacturers of foods, biofuels, specialty chemicals, power and related products using sugarcane as the primary feedstock, announced that it has raised Rs 90 crore ($15 million) in equity, from funds managed by Mandala Capital.

In pursuit of its vision to increase the current level of extracted value, Godavari has been investing heavily in innovation, research and collaboration in the production of sugar, power and ethanol and in the manufacture of value added, complex chemicals derived from ethanol as well as the waste products of the sugar refining process.

The funds invested by Mandala Capital will be used for phase I of this strategy, which involves a new manufacturing plant for specialty chemicals, an increased capacity for ethanol production, debottlenecking of existing plants and strengthening the company's utility infrastructure.

It will also fund an expanded facility for R&D. Godavari expects a turnover exceeding Rs 1,200 crores for the year ended March 2016.

Mr Samir Somaiya, chairman, Godavari Biorefineries, said, "....For us, innovation in green chemistry is a source of growth and expansion for the company as well as our commitment to the triple bottom line of social, ecological and financial gain."

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

BusinessWire India.com - Healthcare & biotechnology

Bwi-logo

Philip Morris International Announces €300 Million Investment in Smoke-Free

Wednesday, 22 Mar 2017   |   Philip Morris International

Business Wire India Converting existing cigarette factory in Greece into a production facility for

Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter® and Connectivity

Tuesday, 21 Mar 2017   |   Masimo

Business Wire India Masimo (NASDAQ: MASI) announced the CE marking of noninvasive blood pressure (NIBP)

Boehringer Ingelheim Phase III study now enrolling patients with progressive

Monday, 20 Mar 2017   |   Boehringer Ingelheim

Business Wire India For the first time, patients with different fibrosing lung diseases will be included

BusinessWire India.com - Pharmaceutical

Bwi-logo

Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter® and Connectivity

Tuesday, 21 Mar 2017   |   Masimo

Business Wire India Masimo (NASDAQ: MASI) announced the CE marking of noninvasive blood pressure (NIBP)

Boehringer Ingelheim Phase III study now enrolling patients with progressive

Monday, 20 Mar 2017   |   Boehringer Ingelheim

Business Wire India For the first time, patients with different fibrosing lung diseases will be included

Uninterrupted Pradaxa® Showed Less Major Bleeding than Warfarin in Atrial

Monday, 20 Mar 2017   |   Boehringer Ingelheim

Business Wire India In the RE-CIRCUIT® trial, there were less major bleeding and fewer serious adverse

BusinessWire India.com - Medical Devices

Bwi-logo

Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter® and Connectivity

Tuesday, 21 Mar 2017   |   Masimo

Business Wire India Masimo (NASDAQ: MASI) announced the CE marking of noninvasive blood pressure (NIBP)

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X